Compare PCRX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | NEO |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | 2008 |
| Metric | PCRX | NEO |
|---|---|---|
| Price | $22.83 | $8.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $35.33 | $11.14 |
| AVG Volume (30 Days) | 736.7K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $9.77 | $10.63 |
| Revenue Next Year | $9.71 | $9.73 |
| P/E Ratio | $140.38 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $4.72 |
| 52 Week High | $27.99 | $13.74 |
| Indicator | PCRX | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 23.47 |
| Support Level | $20.41 | $7.07 |
| Resistance Level | $23.82 | $8.89 |
| Average True Range (ATR) | 1.01 | 0.46 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 68.81 | 2.75 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.